Publication:
Assessment of serum endocan levels in patients with beta-thalassemia minor

Simple item page
dc.contributor.authorZorlu, Mehmet
dc.contributor.authorOzer, Ömer Faruk
dc.contributor.authorKaratoprak, Cumali
dc.contributor.authorKıskaç, Muharrem
dc.contributor.authorÇakırca, Mustafa
dc.contributor.institutionauthorZORLU, MEHMET
dc.contributor.institutionauthorÖZER, ÖMER FARUK
dc.contributor.institutionauthorKARATOPRAK, CUMALİ
dc.date.accessioned2022-03-07T20:59:16Z
dc.date.available2022-03-07T20:59:16Z
dc.date.issued2022-02-01T00:00:00Z
dc.description.abstractObjective: Beta-thalassemia minor is a blood disease caused by a hereditary decrease in beta-globin synthesis, frequently leading to hypochromic microcytic anemia. Formerly called endothelial cell-specific molecule 1, endocan is a proteoglycan released by vascular endothelial cells in many organs. Our aim was to investigate the relationship between the beta-thalassemia minor patients and the healthy control group in terms of serum endocan level. Methods: The study was performed in a total of 80 subjects. They were divided into two groups, the beta-thalassemia minor group (n=40) and the healthy control group (n=40). Serum endocan levels, age, sex, body mass index value, and tobacco use data of these groups were compared. Results: No statistically significant difference was detected between the two groups in terms of age, sex, and body mass index values (p>0.05). Endocan levels were measured to be 206.85±88.1 pg/mL in the beta-thalassemia minor group and 236.1±162.8 pg/mL in the control group with no significant difference between the groups in terms of serum endocan levels (p>0.05). Conclusions: In our study, there was no change in endocan level in beta-thalassemia minor. This might be because serum endocan levels are affected by multi-factorial reasons. Serum endocan levels may be altered secondarily to decreased beta-globin chain, increased sympathetic activity due to anemia, or platelet dysfunction induced by oxidative stress in beta-thalassemia minor. Further multicenter studies involving more patients are necessary to demonstrate this.
dc.identifier.doi10.1590/1806-9282.20210753
dc.identifier.pubmed35239873
dc.identifier.urihttp://hdl.handle.net/20.500.12645/30430
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectThalassemia
dc.subjectAnemia
dc.subjectEndothelial cells
dc.subjectProteoglycan
dc.titleAssessment of serum endocan levels in patients with beta-thalassemia minor
dc.typeArticle
dspace.entity.typePublication
local.avesis.id5da70a4d-e287-41bd-bea4-d3c6804d02a4
local.publication.isinternational1
relation.isAuthorOfPublication72084e17-e46e-438f-925e-0a24ad5f9850
relation.isAuthorOfPublicationf5267834-a664-4da6-89f3-ae19762e1423
relation.isAuthorOfPublicationb04cfc56-9dea-4145-a140-c66dc7ace166
relation.isAuthorOfPublication.latestForDiscovery72084e17-e46e-438f-925e-0a24ad5f9850
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Assessment of serum endocan levels in patients with betathalassemia minor.pdf
Size:
188.71 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler